Rodman & Renshaw Maintains Sequenom Market Perform

Rodman & Renshaw maintained its Sequenom SQNM Market Perform rating in a research report published today. In the report, Rodman & Renshaw states, "The company has selected MaterniT21 as the brand name for its proprietary T21 LDT, and is expected to launch the test in late 2011 or early 2012, following the publication of study results from the pivotal Women and Infants clinical validation study to evaluate the clinical performance of the Down syndrome test. The manuscript has been submitted for publication." Shares of Sequenom were trading at $5.92 at the time of posting, down 7.21% from Thursday's market close.